Core Viewpoint - TuHURA Biosciences and Kineta have successfully completed stockholder meetings, approving a merger and key proposals, including an increase in authorized shares and reincorporation in Delaware [1][2]. Company Overview - TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing technologies to overcome resistance to cancer immunotherapy [4]. - Kineta, Inc. is a clinical-stage biotechnology company dedicated to creating next-generation immunotherapies to address challenges in current cancer treatments [8]. Merger Details - TuHURA stockholders approved all proposals at the TuHURA Special Meeting, including increasing authorized shares to 200 million [1]. - Kineta stockholders also approved the merger with TuHURA at their Special Meeting [2]. - The merger is expected to close soon after satisfying remaining conditions [2]. Product Development - TuHURA's lead product, IFx-2.0, aims to overcome primary resistance to checkpoint inhibitors and is preparing for a Phase 3 trial in advanced Merkel Cell Carcinoma [5]. - TuHURA is also developing bi-specific antibody drug conjugates targeting Myeloid Derived Suppressor Cells to enhance immune response [6]. - Kineta's pipeline includes KVA12123, a VISTA blocking immunotherapy in Phase 1/2 trials, showing strong tumor growth inhibition in preclinical models [9]. Financial and Strategic Context - Kineta underwent a corporate restructuring in February 2024 to reduce expenses and preserve cash, including workforce reductions and halting new patient enrollment in trials [10]. - The merger aims to maximize stockholder value and enhance the combined company's capabilities in immunotherapy [10].

Core Viewpoint - TuHURA Biosciences, Inc. has secured $12.5 million in a private offering to fund its operations, including a proposed merger with Kineta, Inc. and the initiation of a Phase 3 trial for its lead product, IFx-2.0 [1][5][9] Funding Details - The private placement involves the issuance of 4.6 million shares of common stock at a price of $2.65 per share, representing a 15% discount to the closing price on June 2, 2025 [1] - Approximately $9.0 million of the total offering will be purchased in four equal tranches based on the achievement of specific milestones, with the remaining $3.5 million to be funded by December 31, 2025 [2][7] - The initial closing of the offering is anticipated on June 4, 2025, subject to customary closing conditions [2] Use of Proceeds - The net proceeds from the offering will be used to fund the merger with Kineta, initiate the Phase 3 trial for IFx-2.0, advance Kineta's VISTA-inhibiting antibody to a Phase 2 trial, and cover other working capital needs [5][9] Milestones for Funding - The funding milestones include: - Notification from the FDA that the company is no longer under a partial clinical hold for the Phase 3 trial of IFx-2.0 [7] - Initiation of the Phase 3 trial for IFx-Hu2.0 [7] - Completion of the merger with Kineta [7] Company Overview - TuHURA Biosciences, Inc. is focused on developing novel technologies to overcome resistance to cancer immunotherapy, particularly through its lead product, IFx-2.0, which is designed to enhance the efficacy of existing treatments [11][12] - The company is also advancing a bi-specific antibody drug conjugate and antibody peptide conjugate targeting immune-suppressing cells in the tumor microenvironment [14]

Core Insights - TuHURA Biosciences is advancing its clinical programs, including the initiation of a Phase 3 trial for IFx-Hu2.0 in combination with Keytruda for advanced Merkel cell carcinoma (MCC) [1][3] - The company is targeting the acquisition of Kineta, Inc. and plans to initiate a Phase 2 trial for Kineta's VISTA inhibiting monoclonal antibody in NPM1-mutated acute myeloid leukemia (AML) [2][3] Clinical Development - TuHURA has initiated a Phase 1b/2a trial of IFx-Hu2.0 as adjunctive therapy with pembrolizumab in patients with Merkel cell carcinoma of unknown primary origin (MCCUP) [1][4] - The Phase 3 trial for IFx-Hu2.0 is expected to begin in Q2 2025, pending the lifting of a partial clinical hold by the FDA [3][10] - The Phase 1b/2a trial will include patients with deep-seated tumors who are not eligible for the Phase 3 trial, addressing a significant patient population [3][4] Financial Overview - For the first quarter ended March 31, 2025, research and development expenses were $4.6 million, compared to $3.6 million for the same period in 2024 [6] - General and administrative expenses increased to $2.4 million in Q1 2025 from $1.0 million in Q1 2024 [6] Corporate Updates - TuHURA is in the process of acquiring Kineta, Inc., with the deal expected to close in Q2 2025, subject to financing and other conditions [2][8] - The company appointed Dr. Bertrand Le Bourdonnec as Head of Drug Discovery and Dr. Craig L. Tendler to its Board of Directors, enhancing its leadership team [10] Upcoming Milestones - Q2 2025: Anticipated initiation of the Phase 3 trial for IFx-Hu2.0 and closing of the Kineta acquisition [10] - Q3 2025: Planned initiation of a Phase 2 trial for Kineta's VISTA inhibiting monoclonal antibody in NPM1-mutated AML [10]

Core Insights - TuHURA Biosciences, Inc. is advancing its Phase 3 immune-oncology initiatives, focusing on overcoming resistance to cancer immunotherapy [5][6] - The company announced that abstracts from Kineta Inc. and Moffitt Cancer Center will be presented at the AACR Annual Meeting 2025, showcasing novel therapies for advanced melanoma [1][2] Group 1: Company Developments - TuHURA is set to present initial results from a Phase 1 study of KVA12123, an anti-VISTA antibody, in combination with pembrolizumab for advanced solid tumors [2] - The company is preparing to initiate a Phase 3 trial for its lead product, IFx-2.0, as an adjunctive therapy to Keytruda® for advanced Merkel Cell Carcinoma [6] - TuHURA has entered into a merger agreement with Kineta, Inc. to acquire the rights to KVA12123, with the merger expected to close in Q2 2025 [4] Group 2: Research and Presentations - The accepted abstracts for the AACR Annual Meeting include mechanistic insights into IFx-Hu2.0 responses after prior anti-PD-1 therapy failure [2] - Presentations will take place on April 28, 2025, with specific sessions dedicated to experimental therapeutics and immunology [2][3]